Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alternative venlafaxine kinetics in overdose.

N J Langford1, U Martin, M Ruprah

  • 1West Midlands Centre for Adverse Drug Reaction Reporting, City Hospital, Birmingham, UK. n.j.langford@bham.ac.uk

Journal of Clinical Pharmacy and Therapeutics
|December 11, 2002
PubMed
Summary

Venlafaxine overdose can lead to prolonged effects due to slow metabolism by CYP2D6. This case highlights potential toxicokinetic variations in overdose scenarios.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond clinical toxicology: protecting our poisoned patients.

Journal of the Royal Society of Medicine·2026
Same author

Health and health inequalities impact assessment for non-clinical measures to control COVID-19 in the Basque Country and Navarre (Spain).

Journal of public health research·2022
Same author

Generation of two iPSC clones (MHHi021-A and MHHi021-B) from a patient with hypertrophic cardiomyopathy with p.Arg723Gly mutation in the MYH7 gene.

Stem cell research·2021
Same author

Generation of two human ISG15 knockout iPSC clones using CRISPR/Cas9 editing.

Stem cell research·2020
Same author

Fentanyl patches: Use and Misuse.

Acute medicine·2020
Same author

Drug and therapeutics committees as guardians of safe and rational medicines use.

British journal of clinical pharmacology·2019

Area of Science:

  • Pharmacology
  • Toxicology
  • Clinical Pharmacy

Background:

  • Venlafaxine pharmacokinetics at therapeutic doses are understood.
  • Venlafaxine is metabolized by cytochrome P450 enzymes, notably CYP2D6.
  • Toxicokinetics of venlafaxine in overdose situations require further investigation.

Observation:

  • A case study involving a 33-year-old female with a significant overdose of venlafaxine (3.0 g) and zolpidem (210 mg).
  • The patient experienced sustained symptoms for 24 hours post-ingestion.
  • Plasma pharmacokinetic analysis revealed an extended elimination half-life for venlafaxine, measured at 15.3 hours.

Findings:

  • The prolonged venlafaxine elimination half-life suggests impaired drug metabolism.
  • The patient's metabolic profile is hypothesized to be that of a slow metabolizer for CYP2D6 substrates.

Related Experiment Videos

  • CYP2D6 enzyme polymorphism may significantly influence venlafaxine toxicokinetics in overdose.

    • Implications:

    • This case underscores the importance of considering individual metabolic variations, particularly CYP2D6 polymorphism, in managing venlafaxine overdose.
    • Understanding toxicokinetics can guide clinical management and treatment strategies for overdose patients.
    • Further research into CYP2D6 activity in overdose is warranted to refine patient care protocols.